-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ML-007 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ML-007 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ML-007 in Alzheimer's Disease Drug Details: ML-007 is under development for...
-
Product Insights
NewDyskinesia – Drugs In Development, 2024
Empower your strategies with our Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication. The Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by...
-
Product Insights
NewAutism Spectrum Disorder (ASD) – Drugs In Development, 2024
Empower your strategies with our Autism Spectrum Disorder (ASD) – Drugs In Development, 2024 report and make more profitable business decisions. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication...
-
Product Insights
NewSchizophrenia – Drugs In Development, 2024
Empower your strategies with our Schizophrenia – Drugs In Development, 2024 report and make more profitable business decisions. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia drugs in development market research report provide comprehensive information on the therapeutics under development for Schizophrenia, complete with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DF-9001 in Oropharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DF-9001 in Oropharyngeal Cancer Drug Details: DF-9001 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zolmitriptan in Autism Spectrum Disorder (ASD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zolmitriptan in Autism Spectrum Disorder (ASD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zolmitriptan in Autism Spectrum Disorder (ASD) Drug Details: Zolmitriptan is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fazirsiran Sodium in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Fazirsiran Sodium in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:ARO-AAT is under development for the treatment of liver...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – zolmitriptan
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry zolmitriptan Drug Details Zolmitriptan is under development for the treatment of autism spectrum disorders...
-
Product Insights
Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Schizophrenia include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia pipeline market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Muscarinic Acetylcholine Receptor M4 (CHRM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Muscarinic Acetylcholine Receptor M4 (CHRM4) mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides, and modulation of potassium channels through the action of G proteins. The CHRM4 pipeline market research report provides comprehensive information on the CHRM4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research, and development history as well...